Skip to main content

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review



Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30–40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, subsequent treatment outcomes, and characteristics associated with this subpopulation.


A comprehensive SLR was conducted to identify studies, published from Jan 1995 to May 2019, which focused on insufficient efficacy and/or tolerability to triptans.


Thirty-five publications were identified, of which 22 described randomized controlled trials and open-label studies, and 13 described observational studies. Across studies, multiple objectives and a high amount of variability in methodologies and outcomes were noted. The most commonly applied measures of efficacy were headache pain freedom and pain relief at 2 h. Ten studies assessed efficacy of switching or optimizing treatment in patients with historical insufficient efficacy or tolerability to previous triptan treatment and demonstrated varying levels of success. Factors associated with increased risk of triptan insufficient efficacy included severe baseline headache severity, photophobia, phonophobia, nausea, and depression.


Irrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.

FormalPara Key Summary Points
This systematic literature review identified substantial variability across studies in definitions and methodologies used to identify insufficient efficacy and/or tolerability to triptans for acute treatment of migraine.
Across studies, the most commonly used outcomes to measure efficacy were pain relief and pain freedom at 2 h.
The totality of evidence suggests that a proportion of patients with insufficient efficacy and/or tolerability to one triptan may benefit from switching to a different triptan.
Factors associated with increased risk of insufficient efficacy and/or tolerability to triptans include severe baseline headache severity, photophobia, phonophobia, nausea, and depression.
Findings from this review suggest that a large unmet need remains for people with insufficient efficacy and/or tolerability to triptans, irrespective of the definitions or methodologies used to identify this population.

Digital Features

This article is published with digital features to facilitate understanding of the article. To view digital features for this article go to


Since their introduction in the 1990s, triptans have been considered therapy of choice for the acute treatment of moderate to severe migraine attacks [1]. Triptans act primarily on 5-HT1B/5-HT1D receptors which are present in multiple regions including cerebral blood vessels, sensory trigeminal nerves, and trigeminal nucleus caudalis neurons [2]. Activation of these receptors leads to inhibition of release of pro-inflammatory neuropeptides and vasoconstriction [3]. Triptans have been available to patients in the USA for more than 20 years; estimates from a longitudinal US study that evaluated utilization and reimbursement trends point to an increase in triptan prescriptions from 87,348 in 1993 to 1.2 million in 2013 [4]. Globally, triptan use is more challenging to study, in part because of limited data availability, and partly because triptans are available over-the-counter (OTC) in some countries such as the UK, Germany, New Zealand, and Sweden [5,6,7].

It is estimated that approximately 30–40% of people with migraine are not successfully treated using a triptan, for reasons of insufficient efficacy and/or tolerability [8,9,10]. Factors including route of administration and time from onset of migraine attack to administration have been shown to influence patients’ response to triptans [11, 12]. While methods to assess response vary across studies, it is generally acknowledged that insufficient efficacy and/or tolerability to one triptan does not necessarily predict outcomes with a different triptan. The true population of patients with insufficient efficacy and/or tolerability to triptans is challenging to characterize given the complexity and high level of variability reported across patients, attacks (even within the same person), and treatments [8, 12]. In addition, definitions applied to identify people with triptan insufficient efficacy and/or tolerability vary substantially among studies.

Given the need to better understand this population of patients with migraine and insufficient efficacy and/or tolerability to triptans, we conducted a systematic literature review (SLR) to identify randomized controlled trials (RCTs), open-label studies, and observational studies that focused on evaluating any aspect of this population. Our objectives were to investigate outcomes associated with switching or optimizing acute treatments; to determine definitions and terminologies used to identify and describe this population; and to investigate patient, disease, attack, and treatment characteristics associated with this population. Robust reviews, meta-analyses, and expert clinical perspectives relevant to this topic have been previously published [8, 9, 12,13,14]. However, to our knowledge this is the first SLR with a broad scope specific to this population. This information is increasingly relevant as new classes of acute treatments will become options for patients who have insufficient efficacy, tolerability, or contraindications to triptans.


Data Sources and Searches

We searched the literature for all relevant RCTs and observational studies of patients with migraine who have been treated with triptans. Using the OVID platform, we searched the following databases: EMBASE, Ovid MEDLINE® and Epub Ahead of Print, In-Process and Other Non-Indexed Citations, Daily and Versions®, EBM Reviews (Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effect), PsychINFO, and EconLit. Search strategies are included in Supplementary Material.

The search strategies utilized a combination of free text searching and subject headings. Vocabulary and syntax were adjusted across databases. We also searched for any additional references by hand-searching bibliographies of relevant articles. Grey literature was carefully explored for any relevant publications since 2017 to present, utilizing clinical trial registries ( and WHO Internal Clinical Trials Registry Platform) and conference proceedings (Migraine Trust International Symposium [MTIS], Congress of the International Headache Society [IHC], American Headache Society [AHS] Annual Scientific Meeting, European Headache Federation [EHF] Congress, and American Academy of Neurology [AAN] Annual Meeting).

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Study Selection

Studies were included on the basis of Population, Intervention, Comparator, Outcome, Study design (PICOS) criteria for inclusion and exclusion. Studies published from Jan 1995 to May 2019 which included interventions with triptans versus any comparators and focused on insufficient efficacy and/or tolerability to triptans were screened.

Screening Process and Data Extraction

The systematic review process followed guidelines from the Cochrane Handbook of Systematic Reviews of Interventions (CHSRI) [15]. A researcher (DJ) executed the search strategies in each database and exported the results for abstract screening. In the first phase of screening, two independent analysts (NH and JS) reviewed the titles and abstracts of all retrieved publications. Following this, the same two analysts independently examined full-text publications. Any discrepancies were resolved through discussion or through the involvement of a senior reviewer.

Data extraction from eligible studies, utilizing the data extraction form, was performed by one analyst and checked by another analyst against the source publication. Any disagreements in the assessment of these data were resolved by a senior reviewer.

Bias Assessment and Quality Control

Two analysts independently performed quality assessments of RCTs and observational studies. RCTs were assessed for risk of bias using the CHSRI tool [15]. Non-randomized studies were assessed for bias using the Newcastle–Ottawa Scale (NOS) [16].

Following this step, two independent analysts assessed the quality of RCT publications using the National Institute of Health and Care Excellence (NICE) checklist [17]; for observational studies, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used [18]. This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 2009 guidelines [19]. The PRISMA checklist is provided in the Supplemental Material.

Definitions for Pain Freedom and Pain Relief

When referencing efficacy response throughout this review, “pain freedom” refers to complete elimination of pain at endpoint. Unless otherwise stated, “pain relief” generally refers to a decrease in headache pain severity from moderate or severe at baseline to mild or none at endpoint using a 4-point headache severity scale.


Overall Search Results

The initial literature search yielded 4663 abstracts and 382 sources of grey literature. Following screening of abstracts, 45 full-text publications were reviewed, of which 31 publications met PICOS criteria for inclusion (Supplemental Material, Supplementary Table S1) in the qualitative synthesis. Four grey literature records were included in the qualitative synthesis, resulting in a total of 35 publications (Fig. 1). Risk of bias and quality control assessments were performed on 18 RCTs and seven observational studies; results are summarized in Supplemental Material. Overall, 16 RCT publications were judged to have a low or unclear risk of bias, while two had serious risk. Observational studies were judged to have mild or moderate risk of bias, except for one which was judged to have serious risk. The quality control assessments demonstrated that the source population was well described in 14 publications, inclusion/exclusion criteria were clearly detailed in 16 publications, interventions and comparators were adequately described in all studies except one, and relevant outcomes were assessed in all publications.

Fig. 1

PRISMA diagrama. aRecords retrieved from the Ovid searches included 2227 abstracts from EMBASE, 1073 from MEDLINE, 911 from EBM reviews, 450 from PyschINFO, and 2 from EconLit. AAN American Academy of Neurology, AHS American Headache Society, EHF European Headache Federation, IHS International Headache Society, MTIS Migraine Trust International Symposium, WHO ICTRP World Health Organization International Clinical Trials Registry Platform, PICOS Population, Intervention, Comparator, Outcomes, Study design

In several of the studies identified in this review, the definition for prior insufficiency to triptans was not specific either to only efficacy or only tolerability; the definitions generally could have applied to either or both. Therefore, we used the terminology of insufficient “efficacy and/or tolerability” throughout except in those cases where the definition was clearly attributed to one or the other.

Study Characteristics and Objectives

Of the 35 publications that met criteria for the current analysis, 16 comprised results from randomized, double-blind, placebo-controlled trials; six from open-label studies; and 13 publications disclosed results from observational studies. High-level study overviews with study designs, patient populations, interventions, and outcomes specific to the scope of this review are summarized in Tables 1 and 2. Broader and more detailed descriptions and outcomes of the studies are provided in Supplemental Material (Supplementary Tables S2 and S3). Definitions and terminology used to identify and describe insufficient efficacy and/or tolerability to triptan across the studies are described in Table 3 for RCTs and open-label studies, and in Table 4 for observational studies. Brief summaries of important study characteristics identified within this SLR, with an emphasis on intervention studies are provided.

Table 1 Study characteristics and key results of blinded randomized controlled trials and open-label studies.
Table 2 Study characteristics and key results of observational studies
Table 3 Terminology and definitions used by RCTs and open-label studies to denote insufficient efficacy and/or tolerability to triptans
Table 4 Terminology and definitions used by observational studies to denote insufficient efficacy and/or tolerability to triptans

Terminology and Definitions

The most commonly applied terms to describe people with triptan insufficient efficacy and/or tolerability involved variations of non-response and variations of insufficient response (Tables 3, 4). Lesser used terms involved dissatisfaction and failure to respond. Most studies relied on patients’ self-reports that were largely subjective and allowed for aspects of both self-defined efficacy and tolerability. In studies with definitions that included specific efficacy parameters, pain freedom at 2 h and pain relief at 2 h were the most commonly applied criteria; some of those further designated sustained efficacy or efficacy in two out of three attacks. A small number of studies applied discontinuation of a triptan for reasons of either efficacy or tolerability as criteria.

Switching and Treatment Optimization Study Overview

There were ten switching or treatment optimization studies which were specifically designed to assess efficacy of subsequent acute treatments in patients with historical insufficient efficacy and/or tolerability to triptans (Table 1). Of these ten studies, seven studied patients with prior sumatriptan [20,21,22,23,24,25,26]; one study each studied prior rizatriptan [27], prior treatment with any orally administered triptan [28], and prior treatment with short-acting orally administered triptans [29]. Key efficacy results with subsequent intervention treatments are summarized in Table 1.

Only three of the ten studies screened and validated self-reported prior triptan insufficient efficacy and/or tolerability using an open-label or single-blind run-in phase [20, 21, 23]. In those three studies, 21–36% of patients who reported prior insufficient efficacy to sumatriptan experienced pain relief at 2 h with sumatriptan during the trial. Among the patients with confirmed insufficient efficacy and/or tolerability, for the outcome of pain freedom at 2 h, 6% subsequently responded to naratriptan 2.5 mg, 33% to almotriptan 12.5 mg, and 22% to rizatriptan 10 mg ODT (orally disintegrating tablets). For the outcome of pain relief at 2 h, 25% subsequently responded to naratriptan 2.5 mg, 48% to almotriptan 12.5 mg, and 51% to rizatriptan 10 mg (ODT; over three attacks). In all three studies, patients were instructed to treat the migraine attack when pain was moderate or severe.

Three of the ten studies investigated responses to a different orally administered triptan (monotherapy) without a run-in validation phase. Two were early intervention studies and are discussed in the respective sections [25, 27]. The other, in which patients were instructed to treat while pain was moderate or severe, was conducted in patients who had previously discontinued orally administered sumatriptan [30]. In that study, 35–42% experienced pain freedom at 2 h and 59–70% of patients subsequently treated with eletriptan 40 mg or 80 mg experienced pain relief at 2 h.

Three studies investigating subsequent responses to a higher dose and/or alternative formulation of sumatriptan [24, 26, 28], and one publication describing subsequent response to combination treatment, are summarized in respective sections [29].

In addition to the ten studies described earlier, three subgroup analyses identified and assessed outcomes to subsequent acute treatments in patients with prior triptan insufficient efficacy and/or tolerability from a broader group of patients within RCTs; subsequent treatments investigated were telcagepant, zolmitriptan, ubrogepant, and lasmiditan [31,32,33]. In the analysis assessing outcomes with telcagepant and zolmitriptan, percentage of patients with historical poor triptan response or no triptan use experiencing pain freedom at 2 h was 13% with telcagepant 150 mg, 14% with zolmitriptan 5 mg, 29% with telcagepant 300 mg, and 12% with placebo [31]. The therapeutic benefit of lasmiditan versus placebo for the outcome of pain-free response at 2 h was generally unaffected by prior response to triptan therapy [33]. Response rates for 2-h pain freedom were higher for ubrogepant versus placebo, and the magnitude of benefit was similar across triptan-responder, triptan-insufficient responder, and triptan-naïve patient categories [32].

Early Intervention with a Different Triptan

In two studies, in patients with reported prior triptan insufficient efficacy and/or tolerability, efficacy to a different orally administered triptan as monotherapy was assessed when treatment was administered early (e.g., within 1 h of attack onset) and/or while headache severity was still mild [25, 27]. Across these studies, pain freedom at 2 h was experienced by 30% of patients who took eletriptan 40 mg, and in 45% (zolmitriptan 5 mg) to 58% (rizatriptan 10 mg) of attacks. Pain relief at 2 h was experienced by 64% of patients who took eletriptan 40 mg, and in 73% (zolmitriptan 5 mg) to 81% (rizatriptan 10 mg) of attacks.

Higher Dose and/or Alternative Triptan Formulation

In four studies conducted in patients with prior triptan insufficient efficacy and/or tolerability, efficacy with a higher dose (sumatriptan 100 mg standard oral formulation) and/or alternative triptan formulation [rizatriptan 10 mg ODT, sumatriptan 100 mg rapid release, sumatriptan 6 mg subcutaneous (SC)] was assessed. Pain freedom at 2 h was reported in (a) up to 61% of patients treated orally with sumatriptan 100 mg rapid release, in participants dissatisfied with sumatriptan at a dose less than 100 mg [26], (b) 80% of attacks treated with sumatriptan 100 mg standard formulation in participants with non-response to sumatriptan 50 mg [24], and (c) up to 56% of patients treated with sumatriptan 6 mg SC in participants who had failed to respond to an orally administered triptan [28]. The study assessing rizatriptan 10 mg ODT is described in an earlier section along with the other two studies that included a run-in validation phase [20].

Combination Therapy in People with Insufficient Efficacy and/or Tolerability to Triptans

Three crossover studies investigated efficacy of combination treatment in patients who reported insufficient efficacy and/or tolerability to an orally administered triptan alone [29, 34]. Two were identical studies in patients who had discontinued a short-acting triptan and subsequently used an orally administered combination of sumatriptan 85 mg plus naproxen 500 mg. Sumatriptan plus naproxen was superior to placebo for pain freedom at 2 h (40–44% vs. 14–17%) and sustained pain freedom 2–24 h (26–31% vs. 8%) [29]. The third study investigated efficacy of orally administered naratriptan plus rectally administered prochlorperazine in patients with insufficient efficacy to orally administered naratriptan alone. None of the 14 patients who received this combination reported being pain-free at 2 h and the authors concluded that there was no evidence of benefit by adding prochlorperazine rectal suppository to naratriptan [34].

Treatment of Patients with Allodynia

Two studies identified in this SLR investigated triptan efficacy in patients with migraine with baseline allodynia or symptoms of subcutaneous sensitivity (SCS). In one study, pain freedom at 2 h with rizatriptan 10 mg, administered within 1 h of onset while pain was mild, ranged from 55% to 59% across patients both with and without baseline SCS [35]. At 2 h post dose, treatment with rizatriptan versus placebo led to significantly larger reductions in proportions of patients with SCS. The presence of SCS at time of dosing was not predictive of pain freedom at 2 h; however, presence of SCS at 2 h correlated with lack of pain freedom at 2 h [35]. In the American Migraine Prevalence and Prevention (AMPP) study, in which medication was taken earlier in the course of attacks compared to most clinical trials, lack of pain freedom at 2 h in at least half of the attacks was reported more often in triptan users with allodynia (50%) versus those without allodynia (36%) [36].

Characteristics Potentially Associated with Insufficient Efficacy and/or Tolerability to Triptans

Several observational studies investigated potential predictors and characteristics associated with triptan insufficient efficacy and/or tolerability [36,37,38,39,40,41,42,43,44]. In addition to those observational studies, two subgroup analyses from RCTs investigated predictors of insufficient efficacy within a single attack [35, 45].

Study participants with insufficient efficacy and/or tolerability to triptans were more likely to be younger [40, 41, 44], of female gender [40, 42], and have clinical depression or have more symptoms of depression [36, 40, 41, 44]. Additionally, patients with triptan insufficient efficacy and/or tolerability commonly presented with more severe baseline headache intensity [36, 40, 42, 45], higher headache frequency [36, 44], baseline photophobia, phonophobia, and/or nausea [24, 29, 40, 42, 44, 45], presence of allodynia [36], and were less likely to be on migraine preventive medications [36, 43]. It is not clear from the conference abstract if the timing for presence of allodynia was at time of dosing or over patients’ lifetime [36].

Two studies identified that regular coffee consumption is associated with effectiveness of sumatriptan [40, 44]. One study showed that patients with a polymorphism in serotonin transporter gene were more likely to experience inconsistent response to a single triptan, as measured over three attacks [43]. Another study showed that insufficient efficacy to rizatriptan was correlated with lesser degree of trigeminal activation and lower variations of trigeminal neuropeptides after triptan administration [38]. Other studies showed that patients with triptan insufficient efficacy and/or tolerability were more likely to have higher opioid use, utilize a higher level of healthcare resources, have more rebound headaches, and have worse migraine-specific quality-of-life assessments [37, 39].


This comprehensive literature review identified substantial variability in methodology and definitions involving triptan insufficient efficacy and/or tolerability and focused on extracting clinically relevant evidence to provide value for clinicians and ultimately patients.

Definitions to identify patients with triptan insufficient efficacy commonly involved lack of pain freedom at 2 h and pain relief at 2 h in a single attack. For both outcomes, some definitions further included qualifiers such as achieving outcome over at least two out of three attacks. Some studies relied on prior discontinuation while others were purely subjective self-assessments based on treatment satisfaction. Several studies applied definitions that allowed for either efficacy or tolerability; none applied a definition specific only to tolerability.

The totality of evidence indicates that some people with insufficient response/tolerability to one triptan may benefit from switching to a different triptan. Switching studies that validated prior insufficient efficacy and/or tolerability to sumatriptan showed that approximately two-thirds of the participants did not experience pain relief at 2 h when re-challenged with sumatriptan within the trials [20, 21, 23]. In those studies, approximately 25–50% of patients subsequently experienced pain relief at 2 h with a different triptan. In studies that did not have a run-in validation period, up to two-thirds experienced pain relief at 2 h after subsequent treatment with a different triptan [25, 27, 30]. In two studies that specified early administration of a different oral triptan monotherapy, rates of pain freedom and pain relief at 2 h were relatively high compared to studies that did not treat early [25, 27].

None of the studies investigated subsequent outcomes in patients who had only triptan insufficient tolerability apart from those who had insufficient efficacy. A remaining unresolved question involves how many patients would benefit from a third triptan after failure to respond to an initial two triptans. Data from a claims database study showed that 8% of patients who initiated a triptan had at least three acute treatment changes (not specific to triptans) over a 1-year period [46]. However, none of the studies identified in this SLR assessed outcomes associated with three or more acute treatment changes.

Some studies identified here demonstrated benefit with a higher dose (sumatriptan 50 mg to 100 mg) or different formulation (sumatriptan rapid release, sumatriptan SC, rizatriptan ODT) of a triptan. Some identified benefit by adding a non-steroidal anti-inflammatory drug (NSAID). The combination of a triptan with an NSAID is recognized as a strategy for triptan insufficient efficacy in Canadian, French, German, the UK, and EHF treatment guidelines [47,48,49,50,51].

Terminology commonly used in studies included non-response or non-responder. However, those terms do not offer clear context as to whether the non-response refers to efficacy, tolerability, or both. In addition, lack of optimal response in these patients could be perceived as being a reflection of the patient rather than the treatment. It seems more accurate and empathetic to refer to “efficacy”, “tolerability”, or when not known (which is often the case), “efficacy and/or tolerability” when referring to patients experiencing insufficient response associated with treatment.

This review found that patients with triptan insufficient efficacy and/or tolerability were more likely to have more frequent and severe headaches; were more likely to have baseline photophobia, phonophobia, nausea, and allodynia; and were less likely to be on preventive medications or have regular caffeine intake. Additional studies have corroborated many of these predictors, especially with regard to higher severity of baseline pain, presence of nausea, and presence of photophobia or phonophobia [52, 53]. Some studies showed that patients in this population were more likely to be younger, female, and more likely to have signs of depression. Potential reasons could include that younger patients may have less experience with the natural history of migraine and with managing their individual attacks, and migraine attacks associated with menstruation may be more difficult to treat [54].

Insufficient response to triptans has been shown to result in considerable humanistic burden [55,56,57]. While effective for many, the unmet need remains high in patients using triptans, resulting in the need for newer drug classes [58, 59]. With novel acute treatments emerging, however, the future algorithm for the acute treatment of migraine is not yet established. This includes guidance on the point at which switching to a different medication class should be considered. In the USA, the AHS has recently published a position statement regarding patients who have contraindications to triptans or who have failed to respond or tolerate at least two orally administered triptans. The statement recommends that these patients would be eligible for one of the new acute treatments, namely lasmiditan, ubrogepant, rimegepant, or neuromodulation device [1]. A recently published article not identified in this SLR, provides the response rates for lasmiditan versus placebo in patients who reported good and insufficient response to prior triptan therapy; efficacy was similar across these patient categories [60]. It may become clinically relevant to understand whether response rates of new treatments would be different in people with contraindications to triptans who immediately initiate new novel treatments versus those who have two prior triptan failures.

Increased physician awareness may help better identify patients at risk of insufficient response to triptans [55]. In addition to factors identified here, overuse of over-the-counter (OTC) medication and timing of triptan administration were factors identified in a global real-world study using data obtained from physicians and patients. Patient-Reported Outcomes (PROs) are mostly used in clinical research rather than in clinical practice. However, some PRO tools such as Migraine-Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment (MIDAS), although not specific to acute treatment, might give an idea of impact of attacks [55]. Further, it might be helpful to have some potential specific PRO tools such as Migraine Treatment Optimization Questionnaire (MTOQ) for the acute treatment which may aid physicians in identifying when to consider reassessment of migraine treatment options [55].

Strengths of this review include application of an up-to-date, rigorous systematic and comprehensive approach to identify all published studies in which the population of patients with triptan insufficient efficacy and/or tolerability was specifically assessed. Limitations include the selective use of published data, inclusion of only publications reported in English, and small numbers of patients in several studies. The design characteristics and statistical limitations of the identified studies have the potential to introduce inherent biases and lack validation. As a result of the heterogeneity and lack of uniformity across studies, results from this review are presented as a narrative synthesis without any comparisons across studies. Reliance on retrospective PROs, recall bias, and inter-subject variability also may have affected the findings. Within studies, besides the methodological limitations, there are some other plausible reasons that may contribute towards insufficient response to orally administered triptans including limited bioavailability and the impact of nausea and vomiting [53, 61]. These factors vary between individuals and orally administered triptans. This may makes it difficult to assess true treatment failure rates, especially if a single attack is studied.

Several studies identified here did not apply a paradigm of early treatment that may influence their results and clinical interpretation. The importance of treating migraine attacks with triptans early and/or while headache severity is mild has been demonstrated in various studies, including the foundational “Act when Mild” study [62]. In clinical practice, patients may treat subsequent attacks earlier on the basis of personal experience. Also, given the variable characteristics of migraine treatments, there could be a learning curve when switching acute treatments. This learned behavior is likely to be associated with increased efficacy.


This compilation of results supports the assertion that a large unmet need remains in the acute treatment of migraine. Regardless of the methodologies or definitions applied across studies, a sizeable proportion of patients did not have optimal outcomes to subsequent treatment or strategies. Solutions to improve the management of those impacted could include increased patient and physician education, increased awareness of treatment optimization strategies, and availability of additional treatment options. Future studies can focus on prediction analyses using real-world data such as pharmacy databases to explore best possible treatment options for those with insufficient responses to triptans [58].

An increased level of consistency in defining insufficient efficacy could help identify patients who have the most potential to benefit from optimization of currently available treatments or availability of newly emerging acute treatments.


  1. 1.

    American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.

    Google Scholar 

  2. 2.

    Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56(3):371–81.

    CAS  Google Scholar 

  3. 3.

    Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084–8.

    Google Scholar 

  4. 4.

    Xia Y, Kelton CM, Wigle PR, Heaton PC, Guo JJ. Twenty years of triptans in the United States Medicaid programs: utilization and reimbursement trends from 1993 to 2013. Cephalalgia. 2016;36(14):1305–15.

    Google Scholar 

  5. 5.

    Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs. 2007;21(11):877–83.

    CAS  Google Scholar 

  6. 6.

    Frisk P, Sporrong SK, Ljunggren G, Wettermark B, von Euler M. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden. Eur J Clin Pharmacol. 2016;72(6):747–54.

    Google Scholar 

  7. 7.

    Parkinson B, Gumbie M, Cutler H, Gauld N, Mumford V, Haywood P. Cost-effectiveness of reclassifying triptans in Australia: application of an economic evaluation approach to regulatory decisions. Value Health. 2019;22(3):293–302.

    Google Scholar 

  8. 8.

    Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891–6.

    Google Scholar 

  9. 9.

    Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–58.

    CAS  Google Scholar 

  10. 10.

    Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300–11.

    Google Scholar 

  11. 11.

    Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(Suppl 1):3–9.

    Google Scholar 

  12. 12.

    Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45(2):156–62.

    Google Scholar 

  13. 13.

    Messali AJ, Yang M, Gillard P, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54(7):1120–30.

    Google Scholar 

  14. 14.

    Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–35.

    Google Scholar 

  15. 15.

    The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March 2011. Accessed Mar 19, 2020.

  16. 16.

    Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottowa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2019. Accessed Mar 19, 2020.

  17. 17.

    National Institute for Health and Clinical Excellence. Methods for development of NICE public health guidance (third edition); 2012. Accessed Mar 19, 2020.

  18. 18.

    STROBE. STROBE checklist for cohort, case-control, and cross-sectional studies; 2009. Accessed Mar 19, 2020.

  19. 19.

    Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

    Google Scholar 

  20. 20.

    Seeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011;31(7):786–96.

    Google Scholar 

  21. 21.

    Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin. 2005;21(10):1603–10.

    CAS  Google Scholar 

  22. 22.

    Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23(6):463–71.

    CAS  Google Scholar 

  23. 23.

    Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O’Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000;40(7):513–20.

    CAS  Google Scholar 

  24. 24.

    Landy S, McGinnis J. Early migraine intervention with sumatriptan 100 mg in patients with a history of nonresponse to sumatriptan 50 mg: an open-label, prospective study of multiple attacks. Curr Ther Res Clin Exp. 2004;65(4):353–9.

    CAS  Google Scholar 

  25. 25.

    Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache. 2000;40(6):464–5.

    CAS  Google Scholar 

  26. 26.

    Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract. 2008;62(12):1889–99.

    CAS  Google Scholar 

  27. 27.

    Goldstein J, Tiseo PT, Albert KS, Li C, Sikes CR. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache. 2006;46(7):1142–50.

    Google Scholar 

  28. 28.

    Diamond S, Freitag FG, Feoktistov A, Nissan G. Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans. J Headache Pain. 2007;8(1):13–8.

    CAS  Google Scholar 

  29. 29.

    Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49(7):971–82.

    Google Scholar 

  30. 30.

    Färkkilä M, Diener H-C, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–13.

    Google Scholar 

  31. 31.

    Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient’s historical triptan response. Headache. 2011;51(1):64–72.

    Google Scholar 

  32. 32.

    Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Ubrogepant is effective for the acute treatment of migraine in patients with an insufficient response to triptans (P3.10-024). Neurology. 2019;92(15 Suppl):P3.10-024.

    Google Scholar 

  33. 33.

    Knievel KLL, Buchanan A, et al. Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy. 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches, Florence, Italy. 28–30 September 2018. J Headache Pain. 2018;19(Suppl 1):32–3.

    Google Scholar 

  34. 34.

    Tietjen GE, Athanas K, Utley C, Herial NA, Khuder SA. The combination of naratriptan and prochlorperazine in migraine treatment. Headache. 2005;45(6):751–3.

    Google Scholar 

  35. 35.

    Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia. 2007;27(9):1055–60.

    CAS  Google Scholar 

  36. 36.

    Munjal S, Reed ML, Buse DC, Bennett A, Fanning KM, Lipton RB. The impact of triptan use and allodynia on initial and sustained response to medication in episodic migraine (EM): results from American migraine prevalence and prevention study (AMPP). In: Abstracts from the 58th Annual Scientific Meeting, AHS (June 9–16, 2016), 2016; PF04.2016; 56(S1):3–83.

  37. 37.

    Silberstein SD, Shewale AR, Baradaran S, et al. Opioid use, rebound headache, and resource utilization among migraine patients with insufficient response to triptans based on real-world data (S59.007). Neurology. 2019;92(15 Suppl):S59.007.

    Google Scholar 

  38. 38.

    Sarchielli P, Pini LA, Zanchin G, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 2006;26(3):257–65.

    CAS  Google Scholar 

  39. 39.

    Patrick DL, Hurst BC, Hughes J. Further development and testing of the migraine-specific quality of life (MSQOL) measure. Headache. 2000;40(7):550–60.

    CAS  Google Scholar 

  40. 40.

    Peng K, Fuh J, Wang S. The effectiveness and adverse events of sumatriptan: who are susceptible? In: Abstracts from the 58th Annual Scientific Meeting, AHS (June 9–16, 2016), 2016; PF04.2016; 56(S1):3–83.

  41. 41.

    Seo JG, Park SP. Factors associated with frovatriptan response in patients with migraine: a prospective, observational study. Cephalalgia. 2016;36(5):493–8.

    Google Scholar 

  42. 42.

    Sheftell F, Almas M, Weeks R, Mathew NT, Pitman V, Lipton RB. Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia. 2010;30(7):838–46.

    Google Scholar 

  43. 43.

    Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol. 2010;641(2–3):82–7.

    CAS  Google Scholar 

  44. 44.

    Wang S-J, Peng K-P, Fuh J-L, Chen S-P, Wang Y-F. Sumatriptan response and predictors in migraine patients: a large clinic-based cohort study. Cephalalgia. 2017;37(1_suppl):25–51.

    Google Scholar 

  45. 45.

    Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia. 2008;28(1):35–40.

    Google Scholar 

  46. 46.

    Lombard L, Schroeder K, Nichols R, Kar-Chan Choong C, Ye W. Characteristics, treatment patterns, and healthcare resource utilization in patients with migraine who initiated a triptan. Headache. 2018;58(S2):182–183 [PS54].

  47. 47.

    Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci. 2019;3(1):2514183X18823377.

    Google Scholar 

  48. 48.

    Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain. 2014;5:2.

    Google Scholar 

  49. 49.

    National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management. Clinical guideline [CG150]; 2012. Accessed Mar 19, 2020.

  50. 50.

    Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(5 Suppl 3):S1–80.

    Google Scholar 

  51. 51.

    Steiner TJ, Jensen R, Katsarava Z, Linde M. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57.

    CAS  Google Scholar 

  52. 52.

    Christoph-Diener H, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology. 2004;63(3):520–4.

    CAS  Google Scholar 

  53. 53.

    Newman LC. Why triptan treatment can fail: focus on gastrointestinal manifestations of migraine. Headache. 2013;53(Suppl 1):11–6.

    Google Scholar 

  54. 54.

    Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. Headache. 2017;57(2):194–208.

    Google Scholar 

  55. 55.

    Lombard L, Farrar M, Ye W, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41.

    CAS  Google Scholar 

  56. 56.

    Zebenholzer K, Gall W, Wöber C. Use and overuse of triptans in Austria—a survey based on nationwide healthcare claims data. J Headache Pain. 2018;19(1):34.

    Google Scholar 

  57. 57.

    Piccinni C, Cevoli S, Ronconi G, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20(1):74.

    Google Scholar 

  58. 58.

    Hansen TF, Chalmer MA, Haspang TM, Kogelman L, Olesen J. Predicting treatment response using pharmacy register in migraine. J Headache Pain. 2019;20(1):31.

    Google Scholar 

  59. 59.

    van Hoogstraten WS, Van Den Brink AM. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. J Headache Pain. 2019;20(1):54.

    Google Scholar 

  60. 60.

    Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19–27.

    Google Scholar 

  61. 61.

    Ferrari A, Tiraferri I, Neri L, Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain. 2011;12(1):5–12.

    CAS  Google Scholar 

  62. 62.

    Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28(4):383–91.

    CAS  Google Scholar 

  63. 63.

    Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29(11):1133–48.

    CAS  Google Scholar 

  64. 64.

    Scott RJ, Aitchison WR, Barker PR, McLaren GI. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. QJM. 1996;89(8):613–22.

    CAS  Google Scholar 

  65. 65.

    Cady R. CGRP, estrogen, cortisol, VIP, α-amylase, PGE2, PGI2 and β-endorphin levels in menstrual migraine before and after treximet; 2014. Accessed Mar 19, 2020.

  66. 66.

    Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E. Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post hoc analysis of four randomized trials of eletriptan 40 mg. Cephalalgia. 2014;34(5):376–81.

    Google Scholar 

  67. 67.

    Spierings EL, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med. 2009;10(4):633–8.

    Google Scholar 

  68. 68.

    Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44(7):661–8.

    Google Scholar 

  69. 69.

    al Deeb S, al Kawi Z, Yaqub B, Bohlega S, Cheung P. Sumatriptan treatment of acute migraine attacks in a Saudi population. Clin Neurol Neurosurg. 1997;99(1):23–5.

    CAS  Google Scholar 

  70. 70.

    Miljkovic S, Smajlovic D, Crncevic S, et al. Efficient therapy for treatment of migraine without aura: ergotamine based drugs or sumatriptan. 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches. J Headache Pain. 2018;19(1):80.

  71. 71.

    Linder, S.L. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache J Head Face Pain 1996;36:419–22.

    CAS  Google Scholar 

  72. 72.

    Alam A, Munjal S, Reed ML. Triptan use and discontinuation in a representative sample of persons with migraine: results from Migraine in America symptoms and treatment (mast) study. Presented at 60th Annual Scientific Meeting American Headache Society® June 28‐July 1, 2018 San Francisco Marriott Marquis San Francisco, CA. Headache J Head Face Pain. 2018;58(Suppl.2):68–69.

Download references



This research as well as journal’s Rapid Service and Open Access Fees was funded by Eli Lilly and Company.

Medical Writing Assistance Editorial, and Other Assistance

Authors would like to thank Dr. Messoud Ashina for his suggestions on the article. Darren Joe (DJ) and Jack Said (JS), employees of Adelphi Values, were involved in executing the search and abstract screening for the project. Sriram Govindan and Richi Taneja, employees of Eli Lilly Service India Private Limited at the time of manuscript preparation, provided writing support. Uma Jyothi Kommoju, employee of Eli Lilly Services India Private Limited, provided writing support at the time of revision of the manuscript.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Andrew Buchanan, Louise Lombard, Li Shen Loo, and Brandy R Matthews are employees of Eli Lilly and Company and may be minor stockholders. Daisy Bridge, Ben Rousseau and Natasha Hopwood are employees of Adelphi Values. Elizabeth Leroux has received compensation for serving on advisory boards, speaking, and/or consulting from Allergan, Eli Lilly and Company, Novartis, Tribute Pharmaceuticals, McKesson Canada, Aralez Pharmaceuticals, Medscape and Teva Neurosciences; serves as president of the Canadian Headache Society. Uwe Reuter has received speaker fees and honorarium for consulting from Amgen, Allergan, Co-Lucid, Lilly Pharma, Medscape, Novartis, StreaMedUp, and TEVA Pharma.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

All data generated or analyzed during this study are included in this published article/as supplementary information files.

Author information



Corresponding author

Correspondence to Andrew Buchanan.

Additional information

Digital Features

To view digital features for this article go to

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 2095 kb)

Supplementary material 2 (DOCX 107 kb)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Leroux, E., Buchanan, A., Lombard, L. et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther 37, 4765–4796 (2020).

Download citation


  • Acute treatment
  • Insufficient efficacy and/or tolerability to triptans
  • Migraine
  • Triptans
  • Triptan non-responders
  • Triptan response